All Day Stocks

[Let's Roll]

$RGBP "The optimization process of small molecule development is iterative. It requires a series of compounds to be synthesized and their activity to be understood. By doing this repeatedly and learning about the relationship between structure and activity, optimized compounds are generated," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "We are on track and on schedule. The next two months will be very important as we define the key portions of the structures that relate to activity in the protein molecule."

https://finance.yahoo.com/news/regen-biopharma-inc-provides-nr2f6-120000232.html